CTBO (Cantabio Pharmaceuticals) Retained Earnings: $-4.81 Mil (As of Dec. 2018)


What is Cantabio Pharmaceuticals Retained Earnings?

Cantabio Pharmaceuticals CTBO Retained Earnings is $-4.81 Mil as of Dec. 2018.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Cantabio Pharmaceuticals's retained earnings for the quarter that ended in Dec. 2018 was $-4.81 Mil.

Cantabio Pharmaceuticals's quarterly retained earnings declined from Jun. 2018 ($-4.59 Mil) to Sep. 2018 ($-5.16 Mil) but then increased from Sep. 2018 ($-5.16 Mil) to Dec. 2018 ($-4.81 Mil).

Cantabio Pharmaceuticals's annual retained earnings declined from Mar. 2016 ($-1.00 Mil) to Mar. 2017 ($-2.11 Mil) and declined from Mar. 2017 ($-2.11 Mil) to Mar. 2018 ($-4.12 Mil).


Cantabio Pharmaceuticals  (OTCPK:CTBO) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Cantabio Pharmaceuticals Retained Earnings Historical Data

* Premium members only.

The historical data trend for Cantabio Pharmaceuticals's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantabio Pharmaceuticals Retained Earnings Chart

Cantabio Pharmaceuticals Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
Retained Earnings
Get a 7-Day Free Trial -0.12 -0.23 -1.00 -2.11 -4.12

Cantabio Pharmaceuticals Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.27 -4.12 -4.59 -5.16 -4.81

Cantabio Pharmaceuticals Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-4.81 Mil mean?
Cantabio Pharmaceuticals (CTBO) has a Retained Earnings of $-4.81 Mil as of Dec. 2018. Retained earnings is the amount of net income not issued to shareholders. View historical data on Cantabio Pharmaceuticals and its competitors.
Is Cantabio Pharmaceuticals' Retained Earnings too high?
Cantabio Pharmaceuticals' current Retained Earnings is $-4.81 Mil.
How does Cantabio Pharmaceuticals' Retained Earnings compare to TNTY and ETNI?
Cantabio Pharmaceuticals' Retained Earnings of $-4.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Cantabio Pharmaceuticals and its competitors. Cantabio Pharmaceuticals's current Retained Earnings is $-4.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantabio Pharmaceuticals stock overvalued right now?
Cantabio Pharmaceuticals (CTBO) has a current Retained Earnings of $-4.81 Mil. The current Retained Earnings is $-4.81 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Cantabio Pharmaceuticals (CTBO), the current Retained Earnings is $-4.81 Mil as of Dec. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantabio Pharmaceuticals Business Description

Address 1250 Oakmead Parkway, Sunnyvale, CA, USA, 94085
Cantabio Pharmaceuticals Inc is the United States based preclinical stage biotechnology company. It is focused on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson's disease and Alzheimer's disease and other related diseases. In addition, In addition, it is also engaged in the development of therapeutic proteins that can pass through the blood-brain barrier and supplement in vivo levels of proteins which display loss of function during disease conditions.